AcuCort AB (publ) (XSAT:ACUC)

Market Cap	145.36M
Revenue (ttm)	8.00M
Net Income (ttm)	-24.08M
Shares Out	234.44M
EPS (ttm)	-0.15
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	169,324
Average Volume	218,704
Open	0.6030
Previous Close	0.6190
Day's Range	0.5900 - 0.6240
52-Week Range	0.5000 - 1.2000
Beta	1.33
RSI	54.26
Earnings Date	Nov 14, 2025

About AcuCort AB

AcuCort AB (publ) develops and commercializes glucocorticoid dexamethasone films for the treatment of acute allergic conditions. It offers Zeqmelit, a medicine used for the treatment of severe and acute allergic reactions, croup in children, and chemotherapy-induced nausea and vomiting, as well as for the treatment of COVID-19 patients who need supplemental oxygen treatment. AcuCort AB (publ) was incorporated in 2006 and is based in Lund, Sweden.

• Industry: Pharmaceutical Preparations
• Founded: 2006
• Employees: 4
• Stock Exchange: Spotlight Stock Market
• Ticker Symbol: ACUC

Financial Performance

In 2024, AcuCort AB's revenue was 7.72 million, an increase of 17.07% compared to the previous year's 6.59 million. Losses were -17.40 million, 27.1% more than in 2023.